Management of Immune Checkpoint Inhibitor Toxicities - PMC The recognition of symptoms by physicians and patient is necessary to resolve them rapidly and adapt treatment to allow the toxicity to resolve Keywords: immune check point inhibitor, toxicity, corticosteroids, immunosuppressive treatments Introduction Immune Checkpoint Inhibitors (ICI) have radically changed the treatment of several cancers
Management of toxicities from immunotherapy: ESMO Clinical . . . Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Management of Immune-Related Adverse Events in Patients . . . PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy
Long-Term Toxicity of Immune Checkpoint Inhibitors This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limiting the value of conventional adverse event grading systems
Toxicity in the era of immune checkpoint inhibitor therapy ICI therapy resumption after toxicity is a critical decision, which necessitates balancing therapeutic benefits and potential risk of recurrence Future directions ICI therapy has revolutionized the management of cancer over the past decade and is expected to continue advancing
Toxicities associated with checkpoint inhibitors—an overview Immunotherapy has an increasing role in the management of cancer, both in metastatic disease and as an adjuvant therapy However, sensitization of the immune system with checkpoint inhibitors comes with a unique side effect profile Full
Immune mechanisms of toxicity from checkpoint inhibitors The immune targets of checkpoint inhibitor toxicities are unknown and may be toxicity dependent (e g , the microbiome for colitis and muscles proteins for myocarditis) Circulating effector memory cells may indicate an elevated risk of checkpoint inhibitor toxicity Immunotherapy has changed the treatment landscape for cancer over the past decade